礼来收购传闻搅动市场,法国生物科技企业Abivax股价应声大涨

智通财经
Dec 10, 2025

智通财经APP获悉,法国生物科技公司Abivax(ABVX.US)周三在巴黎股市和美股盘前走高,此次有报道指出,此番股价异动源于市场对减肥药巨头礼来(LLY.US)可能发起收购要约的猜测。

作为一家临床阶段生物科技企业,Abivax的核心在研产品obefazimod主要用于治疗溃疡性结肠炎等炎症性疾病。截至发稿,该公司股价在巴黎股市上涨逾10%,对应市值攀升至约80亿欧元(折合93亿美元),较今年年初5亿欧元的估值实现大幅跃升。美股盘前,该股涨超11%。

“此番股价波动的核心驱动因素,是市场对于潜在收购交易的猜测,”Stifel分析师Damien Choplain表示。

礼来对此回应称:“我们不对业务发展活动发表评论。”

事实上,这家总部位于巴黎的企业早已不是首次卷入收购传闻。金融情报机构Betaville此前于9月和11月两度发布关于Abivax可能被收购的“未经核实”市场猜测,均曾推动其美国存托凭证(ADR)价格上涨。

回溯今年7月,Abivax曾公布重磅利好:其每日一次口服的obefazimod,在两项治疗溃疡性结肠炎的Ⅲ期临床试验中均达到主要终点,消息一出,公司股价随即迎来暴涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10